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ABSTRACT
Novel Withanolide chemical genetic probes identify the in
vivo binding target of withaferin A, which is the intermediate
?lament type III protein vimentin. In addition, a Withanolide
based small molecule screening method screens drug candi
dates that target intermediate ?lament type III proteins. The
method includes introducing a tagged linker covalently
bonded to the Withanolide molecule to form a Withanolide

probe. Better or alternative small molecule compounds as
potential drug candidates can be generated based on their

likely af?nity for the determined binding site in vimentin. The
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ai?nity labeled Withanolide can also be used to ?nd interme
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nolide-biotin analog. The Withanolide probes can be used to
monitor expression of vimentin, in tumor samples or other
diseased tissues. Withaferin analogs can be used as a treat
ment for diverse vimentin-associated disorders, such as can

Tohda et al. Scienti?c basis for the anti-dementia drugs of constitu

cers, angio?brotic diseases, and chronic in?ammation.

diate ?lament-associated proteins using chemical proteomics

ents from Ashwagandha (Withania somnifera). J. Trad. Med. 2005,
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WITHANOLIDES, PROBES AND BINDING

seemingly provides the potential for isolating a small mol
ecule binding target. Unfortunately, current techniques of
biotin a?inity tagging have not realized the full potential of
isolating the binding target for small molecule agents due, in

TARGETS AND METHODS OF USE
THEREOF

part, to the presence of the biotin attached to the small mol

CROSS-REFERENCE TO RELATED
APPLICATIONS

ecule, which may interfere with the natural binding of the
small molecule analog with its target.
One small molecule is the natural product Withaferin A
(hereinafter “WF ”), which is a potent angiogenesis inhibitor

This patent claims priority to US. provisional patent appli
cation Ser. No. 60/785,972, ?led Mar. 27, 2006, herein incor

that targets the ubiquitin-proteasome pathway in vascular

porated by reference.

endothelial cells. WFA is an important prototype of the witha
nolide class of natural products and is a highly oxygenated

FIELD OF THE INVENTION

steroidal lactone that is found in the medicinal plant Wilhani a

somnifera and its related solanaceas species. The withano

The present invention relates to compounds for targeting
human or animal disease states characterized by aberrant

lides are known to exert very potent and diverse cytotoxic,

expression of the intermediate ?lament type III proteins, such
as vimentin, methods and compounds for detecting interme

nomodulatory activities. Since the early discovery of WFA

anti-stress, cardioactive, central nervous system, and immu

during the 1960s, the major interest has been on its anti-tumor

diate ?lament type III proteins, such as vimentin, and com
pounds for use in screening small molecules that target inter

mediate ?lament proteins.

cytotoxic activities. The mesenchymal type-III intermediate
20

?lament (“IF”) protein vimentin plays a critical role in wound

healing, angiogenesis and cancer growth.
The role of vimentin in human and animal disorders,
including those disorders associated with aberrant or elevated

BACKGROUND OF THE INVENTION

Natural products that demonstrate pharmacological e?i
cacy are very important chemical scaffolds for drug design.
While the vast majority of small molecule natural products
will eventually be screened for biological activity, only a
small fraction of these drug-like agents will move forward in

the drug development pipeline. Currently, a considerable
amount of effort is being directed through high throughput

25

2006/0014225; Hertig A, Verine J, Mougenot B, Jouanneau
30

screening to select lead candidates based on their ability to

bind to validated disease-associated protein targets.
A new approach has emerged that employs biologically
active small molecules as cell permeable probes to identify
novel binding targets and to study their function. Since phar
macological activity of a small molecule resides principally

expression of vimentin, and diseases associated with angio
genesis are known in the prior art, e.g. by the following
references, US. Pat. Nos. 5,716,787; 5,932,545; 6,846,841;
7,132,245; 7,175,844; US. Patent application publication no.
C, Ouali N, Sebe P, GlotZ D, Ancel P Y, Rondeau E, Xu
Dubois Y C; Risk factors for early epithelial to mesenchymal
transition in renal grafts, Am J Transplant; 2006 December;

6(12):2937-46 (hereinafter “Hertig et al.”); Kenyon, B. M., et
al., “Effects of Thalidomide and Related Metabolites in a

Mouse Corneal Model of Neovascularization”, Exp. Eye
35

Res., 64:971-978 (1997) (hereinafter “Kenyon et al.”); Cole,

through binding interaction with its hypothetical biological

C. H., et al., “Thalidomide in the management of chronic
graft-versus-host disease in children following bone marrow

target(s) (e.g., protein receptor), it is the discovery of such a
protein receptor is of critical importance in drug develop

transplantation”, Bone Marrow Transplantation, 14:937-942
(1994) (hereinafter “Cole et al.”); Russell, M. E., et al.,

ment. Furthermore, the identi?cation of the speci?c amino
acid of the protein target to which the small molecule binds

40

“Chronic Cardiac Rejection in the LEW to F344 Rat Model”,

J. Clin. Invest., 97(3):833-838 (1996) (hereinafter “Russell et

offers molecular insight into the speci?city of such binding

al.”; KwonY S, Kim J C. Inhibition of corneal neovascular

interactions. Consequently, the use of the binding site infor
mation allows one to look for similar binding sites in other

ization by rapamycin, Exp Mol Med. 2006 Apr. 30; 38(2):

classes of proteins, molecular information that helps expand

45

the target cell types/organisms and clinical indications for the
small molecule drug lead. The discovery of VIAGRATM for
male sexual dysfunction is one such example where research
on phoshodiesterase inhibitors for cardiovascular dysfunc
tion led to the serendipitous identi?cation of a novel thera

Expert Opin Biol Ther, 2001 March; 1(2):253-75, Review;

50

peutic area for this class of drugs.

In small molecule protein target discovery research, the
most critical element is the innovative chemical design to
convert a drug-like chemical compound into a useful biologi
cally active chemical probe that affords the ability to use the

173-9 (hereinafter “Kwon et al.”); Zogakis T G, Libutti S K,
General aspects of anti-angiogenesis and cancer therapy,

55

Kirsch M, Santarius T, Black P M, Schackert G, Therapeutic
anti-angiogenesis for malignant brain tumors. Onkologie,
2001 October; 24(5):423 -30. Review hereinafter “Zogakis et
al.”); Manzano R, Peyman G, Khan P, Carvounis P, Kivilcim
M, Ren M, Lake I, CheveZ-Barrios P, Inhibition of experi
mental corneal neovascularization by Bevacizumab(AVAS
TIN), Br] Opthalmol. 2006 Dec. 19 (hereinafter“Manzano et
al.”); Yeh J R, Mohan R, Crews C M, The antiangiogenic
agent TNP-470 requires p53 and p21 CIP/WAF for endothe

reagent for identi?cation of its in vivo protein binding target.

lial cell growth arrest, Proc Natl Acad Sci USA. 2000 Nov. 7;

Careful consideration is paid to not alter any of the small

One recent screening method uses a?inity tagging small

97(23):12782-7 (hereinafter “Yeh et al.”);YuY, Moulton K S,
Khan M K, Vineberg S, Boye E, Davis V M, O’Donnell P E,
Bischoff J, Milstone D S, E-selectin is required for the anti
angiogenic activity of endostatin, Proc Natl Acad Sci U S A.
2004 May 25; 101(21):8005-10 (hereinafter “Yu et al.”);
Murthy R C, McFarland T J, Yoken J, Chen S, Barone C,
Burke D, Zhang Y, Appukuttan B, Stout J T, Corneal trans
duction to inhibit angiogenesis and graft failure, Invest
Opthalmol V is Sci. 2003 May; 44(5):1837-42 (hereinafter
Murthy et al.”); Rogers M S, Rohan R M, Birsner A E,

molecules with biotin to form a small molecule analog, which

D’Amato R J. Genetic loci that control the angiogenic

molecule’s biological activities when the synthetic analog is
generated. In addition, it is also important that a level of

speci?city for protein binding is demonstrated. Chemical

60

radioisotope tagging is commonly used to generate a radio
labeled analog of the small molecule to help in protein target
detection. However, a major drawback with this approach is
that this method does not afford a direct means to isolate the

binding target of this agent.

65
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response to basic ?broblast growth factor. FASEB J. 2004

July; 18(10)11050-9 (hereinafter “Rogers et a1.”); Zhang M,

disclosed by Yokota et al., Development of Withaferin A.,
Bioorg Med Chem Lett. (2006), herein incorporated by ref

Volpert O, Shi Y H, Bouck N. Maspin is an angiogenesis

erence.

inhibitor, Nat. Med. 2000 February; 6(2):l96-9 (hereinafter
“Zhang et a1.”); and Mor-Vaknin N, Punturieri A, Sitwala K,

A small molecule screening method comprises generating
an af?nity labeled withanolide analog by binding withanolide

Markovitz D M, Vimentin is secreted by activated macroph
ages, Nat Cell Biol. 2003 January; 5(1):59-63 (hereinafter
“Mor-Vaknin et a1.”); all herein incorporated by reference.
Although the role of vimentin, and diseases associated with
angiogenesis are known in the prior art, the non-cytotoxic
anti-in?ammatory and immunomodulatory mechanisms of

compound to an af?nity tag via a linker group; introducing the
af?nity labeled withanolide analog to a cell culture that has
been exposed to small molecule drug candidates; and con

tacting the af?nity labeled withanolide analog with one of: (i)
a puri?ed protein that has been exposed to one or more small

molecule drug candidates; (ii) a cell extract that has been

WFA have thus far remained rather poorly characterized.
These latter disease-altering activities are highly pertinent to
the practice of ayurveda, a traditional form of Indian medi
cine, which has borne out many effective formulations from
W somnifera, especially for the treatment of chronic human
diseases such as arthritis and female bleeding disorders.

exposed to one or more small molecule drug candidates; and
(iii) a protein mixture that has been exposed to one or more

small molecule drug candidates.
Using the present method, a small molecule canbe selected
as a potential drug based on its binding to the target. In
addition, the present method can be used to determine a target

binding site for the small molecule and/or the withanolide
SUMMARY OF THE INVENTION

20

compound with the target.
In addition, a second small molecule can be generated

The present invention relates to compounds for targeting
functions of intermediate ?lament type III proteins, in par
ticular, vimentin. The ability of certain withanolides to bind
vimentin is positively correlated to the anti-angiogenic and

based on its likely af?nity for the determined target binding

site, leading to other potential drug candidates.
25

anti-in?ammatory activity of this compound class.
The present invention also relates to compounds and meth
ods for detecting intermediate ?lament type III proteins, such
as vimentin. For example, withanolide derivatives with
chemical or radioactive tags can be used as detection probes
and/or assist with the isolation of withanolide binding pro

30

The present invention, in another form thereof, relates to a
method of producing a small molecule probe comprising a
withanolide compound that has been conjugated to an af?nity
tag via a linker group. The af?nity tag may be a biotin moiety
and the linker group may be a C 1 -C20 long hydrocarbon chain
linker.
The present invention, in another form thereof, relates to an

af?nity labeled screening compound analog comprising a

teins and target-associated co-isolated proteins.

withanolide covalently bonded to a linker molecule, which is

The present invention also relates to a method for screening
small molecules as potential drug candidates that interfere
with binding of WFA to its target protein binding site by use
of a tagged withanolide analog, as demonstrated with bioti
nylated WFA. For example, a withanolide analog can be used
to screen drugs that target intermediate ?lament proteins. In
one form, the af?nity tag biotin, which is covalently bonded to
a hydrocarbon linker having a chain of C l-C20 (of structures
shown) covalently bonded to the withanolide.
Affinity tagging with biotin allows for both the detection of
the target protein of the small molecule and the target sites by

itself covalently bonded to an af?nity moiety tag.
Without being bound to any particular theory, the present

isolation of the small molecule-bound protein target using
af?nity chromatography. The isolation of the target bound to
the small molecule analog allows for the determination of the
binding site. From knowing the target binding site, one can
generate and develop tailored new classes of small molecule
compounds, which may be even better drug candidates than

invention in another form, concerns a method for treating
diverse human or animal disorders characterized by aberrant
or elevated levels of vimentin comprising administering an
effective amount of WFA or a withanolide analog compound
40

to an individual or animal in need of treatment therefrom to

bind to vimentin, thereby treating the disease associated with
elevated levels of vimentin. The disorders include but are not
limited to angio?broic diseases such as tumors, macular

edema, proliferative diabetic retinopathy, macular degenera
45

tion, neovascular glaucoma, corneal neovascularization, and
endometriosis and diseases with scar tissue formation such as

scleroderma, keloids, kidney ?brosis, pulmonary ?brosis,
50

cardiac ?brosis, chemotherapy/radiation induced lung ?bro
sis, pancreatitis, in?ammatory bowel disease, Crohn’s dis
ease, hypertrophic scar, nodular fasciitis, eosinophilic fascii

the parental molecule.

tis, Dupuytren’s contracture, general ?brosis syndrome,

Two key aspects, which allow for the isolation of the small
molecule analog bound to its target, are that the placement of
the biotin moiety should not hinder the small molecule’s
pharmacophores and that the small molecule biotin adduct
must be separated by a chemical linker long enough that it
allows the small molecule to enter into living cells and bind to
its target in vivo.
A highly validated approach was used to test the effective
ness of the present screening method using small molecule
analogs labeled with an af?nity tag by designing a WFA
biotin af?nity reagent as a test small molecule analog. The
WFA-biotin af?nity reagent utilized previous known struc

characterized by replacement of normal muscle tissue by
?brous tissue in varying degrees, retroperitoneal ?brosis,
liver ?brosis, and acute ?brosis, chronic in?ammation such as
55

rheumatoid arthritis, and organ transplant failure.
BRIEF DESCRIPTION OF THE FIGURES
60

novel cell-permeable af?nity analog of WFA that retains bio
logical activity and identi?es its covalent binding protein, as

FIG. 1a shows the chemical structures of WFA and l2-D

WS,
FIG. 1b is a Coomassie blue stained gel depicting af?nity

isolation of WFA-B binding proteins,

ture-activity relationship studies to determine the pharma
cophores of WFA. This information was used to generate a

Crohn’s disease, ulcerative colitis, psoriasis, sarcoidosis, and

FIG. lc is a protein blot depicting WFA-B binding to a 56
65

kDa protein in HUVECs,
FIG. 1d is a protein blot depicting WFA-B binding to
vimentin in HUVECs, and

US 8,735,178 B2
6
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FIG. 1e is a protein blot depicting tetrameric soluble ham

ducing a tagged linker covalently bonded to the withanolide

ster vimentin incubated with different doses of WFA or inac

molecule to form a withanolide analog. The linker may be a

C l-C2O long hydrocarbon chain linker and the af?nity tag can

tive congener l2-D WS;

be a biotin moiety.
As a result, the linker spaces the af?nity group suf?ciently
from the small molecule moiety so as to prevent the af?nity

FIG. 2a is a snapshot of a MD-simulated solvent accessible

surface area binding structure showing WFA binding in the
cleft between the A and A' (x-helices of the vimentin tetramer,
FIG. 2b is an enlargement of a portion of FIG. 2a, showing

tag from interfering with the normal binding of the small
molecule with its target. Accordingly, the present invention

the A-ring twist-boat and B-ring half-chair conformation of
WFA accommodated deep within the binding cleft of the
vimentin tetramer,
FIG. 20 is a ribbon model showing hydrogen bonding
between Gln324 of the vimentin A-helix and the Cl position

allows for a more accurate identi?cation of a small mol

ecule’s binding site on a target and identi?cation of the target

binding sites without the af?nity group interfering with the
binding of the small molecule with the target.

oxygen atom, and Asp33 l of the vimentin A'-helix and the C4

The af?nity tag and linker are selected so as to not interfere

hydroxyl group, and
FIG. 2d depicts the alpha orientations of the C5 (OH) and

with the uptake of the small molecule analog by a target cell.

C6-C7 (epoxide) of the inactive withanolide congener l2-D

particularly relevant so long as the linker group suf?ciently
spaces the af?nity group from the small molecule and the
linker group does not adversely effect the binding of the small
molecule with its target. The af?nity tag can be biotin or any

The exact composition or form of the linker group is not

WS appose Cys328 of vimentin;
FIG. 3a depicts tetrameric soluble hamster vimentin poly
merized in the presence of 170 mM NaCl,

FIG. 3b depicts polymerization of tetrameric vimentin in
the presence of 25 uM WFA,

20

Better or alternative potential small molecule compounds
as potential drug candidates can be generated based on their

tures,
FIG. 3d shows that l2-D WS does not disrupt vimentin

likely af?nity for the determined binding site.

polymerization,
FIGS. 3e-3j are micrographs in which the BAECs are

25

a monoclonal anti-vimentin antibody, and co-stained with

phalloidin-rhodamine,
30

do se-responsive increases in vimentin cleavage products pro
duced by WFA treatment, and
FIG. 3l is a western blot depicting higher concentrations
and longer periods of exposure to WFA cause reduction in
levels of the 56 kDa protein;
FIG. 411 comprises an upper panel blot depicting MCF-7
cells which lack endogenous IF proteins which were trans

such as breast cancer, using WithaferinA and other analogues
which also target vimentin. The Withaferin analogs also can
be used as a treatment for other vimentin associated disorders,
35

following structures:

FIG. 4b is a plot showing 208 proteasome preparation
incubated with vehicle, Epoxomicin or WFA in the presence

45

50

cytoskeleton; and
FIG. 511 comprises four panels of various micrographs in

55

jected to corneal chemical injury, and
FIG. 5b are plots quantifying neovascularization from each
group of mice from FIG. 5a.
DETAILED DESCRIPTION

60

A novel withanolide chemical genetic probe is used to

identify, in vivo, the binding target of withaferin A, which is
the intermediate ?lament type III protein vimentin. For
example, a withanolide-based small molecule is used in a

screening method to screen drug candidates that target inter
mediate ?lament type III proteins. The method includes intro

including but not limited to a broad range of angiobibrotic
diseases with scar tissue formation, chronic in?ammation,
and organ transplant failure.

Examples of preferred withanolide analogs include the

24 hour cells treated with either vehicle or 2 uM WFA,

which wild-type mice and vimentin-de?cient mice were sub

other diseased tissues. The Withaferin analogs can be used as
a treatment for vimentin associated cancers, such as epithe

lial-to-mesenchymal transition found in epithelial cancers,

fected with human vimentin cDNA or vector control and after

of LLVY-AMC substrate,
FIG. 40 is a graph of embryonic ?broblast cell lines derived
from vimentin-de?cient mice and wild-type littermates
treated with vehicle or 5 uM WFA,
FIG. 4d is a micrograph showing BAECs transduced with
WFA-modi?ed vimentin and cells stained for vimentin,
FIG. 4e is a micrograph depicting BAECs transduced with
WFA-modi?ed vimentin and stained for actin,
FIG. 4f is a micrograph depicting BAECs transduced with
vehicle-treated vimentin having well distributed orchestra
tion of vimentin ?laments, and
FIG. 4g depicts BAECs transduced with vehicle-treated
vimentin having well distributed orchestration of actin

The af?nity labeled withanolide can also be used to ?nd

intermediate ?lament-associated proteins via chemical pro
teomics by extracting proteins from cells that were exposed to
withanolide-biotin analog. The withanolide probes can be
used to monitor expression of vimentin, in tumor samples or

treated with DMSO (FIGS. 3e, 3f and 3g) or 3 uM WFA
(FIGS. 3h, 3i and 3j) for 18 hours, stained for vimentin using
FIG. 3k is a western blot analysis of HUVECs showing

other appropriate af?nity tag which can be covalently bound
to the linker.

FIG. 30 depicts irregular fragmented aggregated struc

65
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(c) Ra, Rb & Rc are independently 4OiC(:O)-Rd-Re,

-continued

Rd is a straight or branched alkyl With up to 12 carbons or

aralkyl,
(i) Re is iOH, iNHZ, iCl, Br, *1, iF, CF3 or biotin,
digoxigenin, BODIFY (8-chloromethyl-4,4-di?uoro-1,
3,5,7-tetramethyl-4-bora-3a,4a-diaza-s-indacene) suc

cinate, or radioactive ligand iO4C(:O)iR-Rd,
Where R is mono- di- tri-ethyleneglycol; or

(ii) Re is OH, iNHZ, 4Cl, Br, *1, iF, CF3 or biotin,
digoxigenin, BODIFY (8-chloromethyl-4,4-di?uoro-1,
3,5,7-tetramethyl-4-bora-3a,4a-diaza-s-indacene) suc
cinate, or radioactive ligand; or

(d) Ra, Rb & Rc are independently 4OiC(:O)iXi
NHiRe Where X is a straight or branched alkyl With up to
12 carbons or mono. di- tri-ethyleneglycol,

Re is 40H, iNHZ, iCl, Br, *1, iF, CF3 or biotin,

digoxigenin, BODIFY (8-chloromethyl-4,4-di?uoro-1,
3,5,7-tetramethyl-4-bora-3a,4a-diaza-s-indacene) suc
cinate, or radioactive ligand or Rd is i(C:O)iRe,

Re is Cy5.5 acetate, Fluorescein acetate, 2-Naphthoxy

acetate, Benzoyl, Benzoyl benzyl acetate, phloro-ac
etophenone acetate, 4-methoxy-2-hydroxy-benzoate,
Alexa succinate, Coumarin acetate, 1-naphthyl, 1-, or
1,3- or, 1,3,5-methoxy-benzyl, 1 to 5 ?uoro-benzyl or
piperazynyl; or

(e) Ra, Rb & Rc are independently 404C(:O)iXiYi
Z, Where X is a straight or branched alkyl With up to 12
carbons or mono- di- tri-ethyleneglycol

(i)Y is penta, hexa, hepta and octapeptides comprising any
30

combination of amino acids selected from the group

consisting of Leu, Ala, Pro Tyr, lle, hydroxy proline, and
Cys; and Z is (argine)8, Z;OH, iO-benzyl, iNH2;
or

(ii) Y is (argine)8, and erenta, hexa, hepta and octapep
35

tides comprising any combination of amino acids selected

from the group consisting of Leu, Ala, Pro Tyr, lle, hydroxy
proline, and Cys.
The preferred dose for administration of a Withanolide

compound composition in accordance With the present inven
40

tion is that amount Which Will be effective in preventing or
treating a vimentin associated disease such as, but not limited
to cancers, a broad range of angio?brotic diseases With scar

tissue formation, chronic in?ammation, and organ transplant
failure, would readily recognize that this amount Will vary
45

greatly depending on the nature of the disorder and the con
dition of a patient. An “effective amount” of the Withanolide

compound or pharmaceutical agent to be used in accordance
With the invention is intended to mean a nontoxic but suf?
50

55

Where:
(a) Ra, Rb & Rc are 40H; or

(b) Ra, Rb and Rc are independently iO-Rd-Re,

60

Rd is a straight or branched alkyl With up to 12 carbons or

aralkyl,
7-tetramethyl-4-bora-3a,4a-diaza-s-indacene) succinate, or
radioactive ligand; or

species, age, and general condition of the subject, the severity
of the condition being treated, the particular carrier or adju
vant being used and its mode of administration, and the like.
Similarly, the dosing regimen should also be adjusted to suit
the individual to Whom the composition is administered and
Will once again vary With age, weight, metabolism, etc. of the
individual. Accordingly, the “effective amount” of any par
ticular Withanolide compound or composition Will vary based
on the particular circumstances, and an appropriate effective
amount may be determined in each case of application by one

of ordinary skill in the art using only routine experimentation.

Re is 40H, iNHZ, 4Cl, Br, *1, iF, CF3, or biotin,

digoxigenin, BODIFY (8-chloromethyl-4,4-di?uoro-1,3,5,

cient amount of the agent, such that the desired prophylactic
or therapeutic effect is produced. Thus, the exact amount of
the Withanolide compound or a particular agent that is
required Will vary from subject to subject, depending on the

65

It Will be clear to one of ordinary skill in the art, Which
vimentin associated conditions or diseases Will bene?t from
the present treatment, based on the role of vimentin in such
conditions or diseases and the effect the binding of a Witha
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nolide compound or a particular agent to the vimentin has on
the role of vimentin. For example, it will be known to one of

ordinary skill in the art, which angiogenesis diseases, includ
ing cancers, which will bene?t from the present treatment
m

with a withanolide compound or a particular agent in accor

dance with the present treatment method.

The present small molecule screening method in which
small molecule analogs comprising small molecules

ing on what is know in the art with regard to the role of
vimentin with regard to disease conditions such as ?brosis
and in?ammation as discussed in the above background sec
tion, WFA binding to tetrameric vimentin induces ?lamen
tous aggregation in vitro, which manifests in vivo as punctu
ate cytoplasmic aggregates that co-localize with vimentin and
actin. WFA’s potent dominant-negative effect on F-actin

requires vimentin expression and induces apoptosis. Finally,
WFA inhibits capillary growth in a mouse model of corneal
neovascularization, but this drug-induced inhibition is com
promised in vimentin de?cient mice. Thus, WFA is useful for
incorporation as a novel chemical genetic probe of vimentin
functions, and illuminates a potential new molecular target

covalently bonded to an af?nity tag via a linker was estab

lished using various experiments with WFA binding proteins.
These experiments con?rm that af?nity tagged small mol
ecules can be used to determine the speci?c binding sites on

target molecules, such as proteins. From knowing the target

for withanolide-based therapeutics for treating angioprolif

binding sites, new or additional small molecules can be devel

erative and malignant diseases, and as a model for IF protein

oped as potential drug candidates, which have af?nity for the
target binding site. Thus, the present experiments demon

related human dystrophies.
The prototypic withanolide WFA (FIG. 1a), which is abun

strate the effectiveness of a screening method which can be

dant in the Indian medicinal plant Wilhania somnifera, is a

used to determine new potential drug candidates which bind
to those target binding sites.

potent inhibitor of angio genesis and tumor growth. To under

For example, as shown by Eckes, B. et al., Impaired wound
healing in embryonic and adult mice lacking vimentin, J. Cell
Sci. 113, 2455-2462 (2000); and van Beijnum, J. R. et al.,
Gene expression of tumor angiogenesis dissected: speci?c
targeting of colon cancer angiogenic vasculature, Blood 108,

2339-2348 (2006), both herein incorporated by reference, the
small molecule angiogenesis inhibitor WFA binds to tet

rameric vimentin by covalently modifying the cysteine resi
due in its conserved (x-helical coiled coil 2B domain. Build

20

stand the mode of action of this natural product, a chemical

25

genetic approach was exploited that affords isolation of small
molecule binding target(s) in accordance with Crews, C. M.
& Splittgerber, U. Chemical genetics: exploring and control
ling cellular processes with chemical probes, Trends Bio
chem. Sci. 24, 317-320 (1999); Schreiber, S. L., Chemical

genetics resulting from a passion for synthetic organic chem
istry, Bioorg. Med. Chem. 6, 1127-1152 (1998), both herein
incorporated by reference. Towards this end, a novel WFA
biotin analog, WFA-B, was synthesized, as shown below.

Withaferin A

Glycine

long chain linker
NH

Biotin moiety

WFA-Gly-LC-LC-biotin (WFA-B)

US 8,735,178 B2
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To generate the WFA-biotinylated analog, the C2_7

As shown in the blot of FIG. 1d, WFA-B binds vimentin in
HUVECs. The blot of FIG. 1d was produced using cell cul
tures preincubated with DMSO (Veh) or with 5 uM WFA or 1

hydroxyl group of WFA was ?rst derivatized with glycine,
which introduced a free amine functional group for subse
quent biotin coupling. The amine group was coupled with a

uM (WFA*) for 30 minutes and subsequently with 5 uM
WFA-B for 2 hours. Cell lysates prepared in 1% Triton X-100

biotinylated 12-hydrocarbon chain linker to produce WFA

buffer were puri?ed over NEUTRAVIDINTM a?inity col
umns and subjected to SDS-PAGE and western blotted with

Gly-LC-LC-biotin (hereinafter “WFA-B”), as taught by
Yokota,Y., Bargagna-Mohan, P., Ravindranath, P. P., Kim, K.
B. & Mohan, R., Development of Withaferin A analogs as

antivimentin V9 antibody.
Referring now to FIG. 1e, in vitro ligand binding assays

probes of angiogenesis, Bioorg. Med. Chem. Len. 16, 2603
2607 (2006), herein incorporated by reference.

were performed which show that vimentin is bound by
WFA-B in a WFA-competitive manner. The assays were per

formed using soluble hamster vimentin incubated with dif

WFA-B binds to a 56 kDa protein that is irreversibly tar

ferent doses of WFA or inactive congener 12-D WS for 1 hour

geted by WFA in vivo in human umbilical vein endothelial
cells (HUVECs). To isolate this WFA-target, bovine aortic
endothelial cells (BAECs) were treated with WFA-B, and
biotinylated proteins were af?nity-puri?ed over NEUTRA

and subsequently with either 0.3 or 1 uM WFA-B for 1 hour.

The proteins were fractionated by SDS-PAGE, blotted and
biotinylated adduct was detected by streptaviding-HRP with
chemiluminescence.

VIDINTM columns and fractionated by gel electrophoresis.

The WFA-B-a?inity chromatographic approach (FIG. 1b)

Gels stained with Coomassie blue dye con?rmed the isolation

of this 56 kDa protein (FIG. 1b).
Af?nity isolation of WFA-B-binding proteins was con

20

ducted as follows. BAECs were preincubated with DMSO

(Veh) or with 5 uM WFA for 30 minutes and subsequently
with 5 uM WFA-B for 2 hours. Cell lysates prepared in 1%
Triton X-100 buffer were puri?ed over NEUTRAVIDINTM

a?inity columns and subjected to SDS-PAGE. The gel was

25

stained with Coomassie blue. The arrow points to the 56 kDa
protein band and asterisks mark the co-eluted 51 kDa and 43

Next, to identify the amino acid residue(s) of vimentin
covalently modi?ed by WFA, puri?ed hamster vimentin was
incubated with WFA and the protein-ligand complexes sub
jected to tryptic digestion and LC-MS/ MS analysis. A search
for the position of adduct formation (a molecular mass shift of

kDa proteins.
LC-MS/MS characterization of this protein identi?ed the
56 kDa protein as vimentin (27% protein coverage), an IF
protein that is abundant in mesenchymal cells. To further

also led to co-isolation of 51 kDa [3-tubulin and 43 kDa
[3-actin. Since vimentin has been reported to interact with
actin and it is a cargo for microtubule-dependent transport, it
is not unexpected that actin and tubulin would co-isolate with
WFA-B-modi?ed vimentin.

470) in the tryptic fragments of vimentin revealed that the
sole cysteine residue at position 327 (position 328 in human
30

support that vimentin is bound by WFA-B in vivo, HUVECs
were treated with WFA-B in the presence and absence of

unconjugated WFA, and total cellular lysates were gel-frac
tionated and protein blots probed with streptavidin-HRP.

35

Referring to FIG. lc, the blot con?rms that WFA-B binds to
the 56 kDa protein in HUVECs. This experiment was con
ducted using cells preincubated with DMSO or WFA for 30
minutes and subsequently with WFA-B for 2 hours. Soluble
proteins extracted in 1% Triton X-100 were fractionated by

40

SDS-PAGE and blotted. This blot, as well as those of FIGS.

1d and 1e, were developed with Streptavidin-HRP. Biotin
label is incorporated in this 56 kDa protein in a WFA-com
petitive manner.

vimentin) in the (x-helical coil coiled 2B rod domain of

vimentin is uniquely modi?ed by WFA (data now shown). A
three-dimensional model of the WFA-vimentin complex was
developed using x-ray crystal structures of vimentin and
WFA. Molecular modeling studies revealed a stable binding
mode for WFA in the surface binding pocket of tetrameric
vimentin between the pair of head-to-tail (x-helical dimers
(FIG. 2a). In this simulated model, the C3 and C6 carbons of
WFA lie in close proximity to the cysteine residue in the
vimentin A-helix (FIG. 2b), permitting a nucleophilic attack
by this thiol group on the electrophilic carbon centers (FIG.
20). Remarkably, the amino acid residues of vimentin
(Gln324, Cys328 and Asp 331) that make contact with WFA
(FIG. 20) are identical from ?sh to mammals, as shown in the
table below.

Sequence
Listing Identifier

Species

Sequence

Human:

RQAKQES TEYRRQVQALTCEVDS LKGTNESLERQMREMEEN SEQ ID NO: 1

Chimp anz ee :

RQAKQES TEYRRQVQAPTCEVDS LKGTNESLERQMREMEEN SEQ ID NO:

Mac aque:

RQAKQESNEYRRQVQALTCEVDS LKGTNESLERQMREMEEN SEQ ID NO: 3

A . Green monkey:

RQAKQESNEYRRQVQALTCEVDS LKGTNESLERQMREMEEN SEQ ID NO:

4

Rhe sus monkey:

RQAKQESNEYRRQVQALTCEVDS LKGTNESLERQMREMEEN SEQ ID NO:

5

P ig :

RQAKQESNEYRRQVQALTCEVDS LKGTNESLERQMREMEEN SEQ ID NO:

6

Dog :

RQAKQESNEYRRQVQALTCEVDS LKGTNESLEHQMREMEEN SEQ ID NO:

7

Bovine:

RQAKQESNEYRRQVQALTCEVDS LKGTNESLERQMREMEEN SEQ ID NO: 8

Hamst er:

RQAKQESNEYRRQVQALTCEVDS LKGTNESLERQMREMEEN SEQ ID NO:

9

Mouse :

RQAKQESNEYRRQVQALTCEVDS LKGTNESLERQMREMEEN SEQ ID NO:

1O

Rat :

RQAKQESNEYRRQVQALTCEVDS LKGTNESLERQMREMEEN SEQ ID NO:

1l

2
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— cont inued

Sequence
Listing Identifier

Species

Sequence

Chicken:

RQAKQEANEYRRQIQALTCEVDSLKGSNESLERQMREMEEN SEQ ID NO:

Frog:
Fish

12

RQAKQETSDFRRQIQALTCEVDSLKGSNESYERQMREMEEN SEQ ID NO: 13
(Trout) :

RQAKQEANEYRRQVQALTCEVDSLKGTNESMERQMRELEES SEQ ID NO:

As shown from the table, the binding site of WFA in vimen
tin is evolutionarily conserved. Amino acid sequences from
within the 2B domain of vimentins of different vertebrate
species reveal the overall high level of sequence conservation.
The speci?c amino acids that make contact with WFA (bold),

14

and disrupted F-actin in WFA-treated cells compared to con
trols (FIGS. 31', 3j). FIG. 3k is a western blot analysis of
HUVECs which shows dose-responsive increases in vimen
tin cleavage products (arrows) with WFA treatment after 2
hours, as detected with the monoclonal anti-vimentin V9

as determined from our molecular modeling studies, are evo

antibody. FIG. 3l depicts higher concentrations and longer

lutionarily identical.

periods of exposure to WFA (4 hours) cause reduction in
levels of the 56 kDa protein (asterisk) and increased abun

Another feature illustrated by this model is that the orien
tation of C27 hydroxyl group places it outside the binding
cleft; thus, biotinylated WFA is able to retain the ?exibility to

20

bind immobilized NEUTRAVIDINTM after modifying tet
rameric vimentin. On the other hand, the simulated model of
vimentin/the inactive congener 12-D WS (FIG. 2d) reveals
that steric hindrances from the C5 alpha-hydroxyl and the
C6-C7 epoxide of WFA are likely to prevent such a nucleo
philic attack by the reactive thiol group on 12-D WS. This
distinction between these two withanolides in their binding

25

modes with vimentin is further corroborated by comparing
the molecular docking-simulated internuclear distances
between WFA and 12-D WS with vimentin, and this data is
consistent with lack of in vitro binding activity of 12-D WS to
vimentin (FIG. 1d) and the absence of its endothelial cell

The amorphous condensed structure phenotype is not
observed with lower doses of WFA or equivalent high dose of
the inactive congener 12-D WS. To further corroborate that
vimentin aggregation by WFA treatment is associated with

vimentin-positive staining particles in the cytoplasm (com
30

35

40

tion to the ?lament structure in vitro, how chemical modi?
cation of cysteine by WFA affects the vimentin 1F structure
was investigated. Employing soluble tetrameric vimentin in

?lament polymerization assays in vitro, although WFA at
high doses does not block ?lament assembly per se, the drug

forms of vimentin to disappear in a manner similar to WFA
45

Since IF protein aggregation has been shown to negatively

impact the ubiquitin proteasome pathway (UPP) resulting in

3a-3
50

merized in the presence of 170 mM NaCl by incubation at 370
C. for 1 hour. The protein was ?xed with 0.5% glutaralde

hyde, stained with uranyl acetate and observed by transmis
sion electron microscopy. The presence of vehicle solvent
55

FIG. 3b depicts polymerization of tetrameric vimentin in
the presence of 25 uM WFA, which produces extensive ?la
mentous aggregates, and FIG. 30 depicts many irregular frag
mented aggregated structures.As shown in FIG. 3d, 12-D WS

(25 uM) does not disrupt vimentin polymerization.

induced effects in HUVECs (data not shown), data that fur
ther supports the in vivo drug-mimetic effect of this WFA

analog.

tively stained transmission electron micrographs (FIGS.

does not interfere with ?lament formation.

gated. Using western blot analysis of soluble proteins from
HUVECs treated with WFA, dose-dependent (above 2 uM)
increases in vimentin cleavage products became detectable
by 2 hours after drug treatment (FIGS. 3k and 3!). Addition
ally, two-dimensional-westem blot analysis reveals that
WFA-B also causes several full-length (~53-56 kDa) iso

induces formation of ?lamentous aggregates, many of which
display amorphous condensed structures as revealed in nega

FIG. 3a depicts tetrameric soluble hamster vimentin poly

pare FIG. 3e with FIG. 3]). lmportantly, these vimentin par
ticulates strongly co-stain for actin (compare FIG. 3h with
FIG. 3j), exemplifying the role of the WFA-binding domain in
control of cytoskeletal structure through the actin-binding
activity of vimentin 2B domain.
As it became apparent that vimentin targeting by WFA may
initiate signaling events leading to cellular apoptosis, the
effect of WFA on soluble tetrameric vimentin was investi

under oxidizing conditions can participate in disul?de cross

linking between a pair of vimentin dimers leading to disrup

perturbation of the cytoskeleton structure, the drug effects in
BAECs were investigated by immunostaining. Cells treated
with 3 uM WFA showed condensation of vimentin ?laments
around the perinuclear region and the presence of numerous,

targeting activity.
The clinical importance of the cysteine residue in vimentin
lies in its propensity for being preferentially oxidized in
vimentin compared to other cyto skeletal proteins from rheu
matoid arthritis patients. Because this unique cysteine residue

dance of cleavage products of vimentin (arrows).

proteasome inhibition, an investigation as to whether the

UPP-targeting activity of WFA is also regulated in a vimen
tin-dependent manner was undertaken. Employing the widely
used MCF-7 vimentin-de?cient model of Bar, H. et al.,
Forced expression of desmin and desmin mutants in cultured
cells: impact of myopathic missense mutations in the central
coiled-coil domain on network formation, Exp. Cell. Res.

312, 1554-1565 (2006), herein incorporated by reference, it
was determined that co-treatment with WFA increases levels
60

BAECs treated with DMSO (FIGS. 3e, 3g, 31') or 3 uM
WFA (FIGS. 3], 3h, 3j) for 18 hours were stained for vimentin
using a monoclonal anti-vimentin antibody (green) and co
stained with phalloidin-rhodamine (red). The vimentin

of polyubiquitinated proteins in vimentin transfected MCF -7
cells, but not in the vector controls (FIG. 4a). MCF-7 cells
that lack endogenous 1F proteins were transfected with
human vimentin cDNA or a vector control and after 24 hours
cells were treated with either vehicle or 2 uM WFA for 1 hour.

in ?uorescence overlap, reveal the presence of numerous

Cell lysates were prepared and equal amounts of protein
subjected to SDS-PAGE and protein blots probed with anti
ubiquitin antibody. Blots were re-probed with anti-GAPDH

cytoplasmic particulate granules that co-stain for vimentin

antibody.

(FIGS. 3e, 3]) and phalloidin-stained images (FIGS. 3g, 3h),
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Referring to FIG. 4b, 20S proteasome (bovine) preparation

mice, which is consistent with previous reports on impaired

was incubated with vehicle (Con), 0.5 uM, 1.0 HM and 10 uM
WFA or with 10 nM Epoxomicin (pr) in the presence of

angiogenesis in vimentin de?ciency.

LLVY-AMC substrate at room temperature. Fluorescence

cell lines, as shown by Falsey, R. R. et al., Actin micro?lament

readings from triplicate samples were obtained at different
time intervals from the 96-well plate using excitation at 355

aggregation induced by WithaferinA is mediated by annexin
II, Nat. Chem. Biol. 2, 33-38 (2006), herein incorporated by

nm and emission at 430 nm. The release of product was

reference. However, this 36 kDa protein is not detected in in
vivo WFA-af?nity puri?ed proteins from human or bovine
endothelial cells (FIG. 1b), nor was it detected by western

WFA has been recently shown to bind annexin II in cancer

plotted against time for each concentration of inhibitor.
Referring to FIG. 40, embryonic ?broblast cell lines
derived from vimentin-de?cient mice and wild-type litter

blotting of NEUTRAVIDINTM-puri?ed proteins in our stud
ies (data not shown). Thus, differences in the construction of
the biotinylated WFA analogs (e.g., inclusion of a long, linear
hydrocarbon linker between the natural product and biotin),

mates were treated with vehicle or 5 uM WFA for 24 hours.
Cells were harvested and stained with annexin V-FITC and

propidium iodide and extent of apoptosis assessed by ?ow
cytometry. The fold-apoptotis for drug over vehicle-treated
samples for each cell line was plotted (n:2 experiments).

or their applications for target isolation (in vitro versus in vivo
labeling), could account for different targets being bound to
WFA. It is also possible that WFA has context-related, bind
ing speci?cities for different targets in vivo, a speculation that
will need to be rigorously tested.
Vimentin is the primary target of WFA in vivo, and this

Referring to FIG. 4d, BAECs were transduced with WFA
treated vimentin and cells were stained after 18 hours. Cells
transduced with WFA-modi?ed vimentin show condensed

vimentin ?laments localized largely in and around the
nucleus and the presence of vimentin-staining particulates
(FIG. 4e). Cells transduced with vehicle-treated vimentin
show well distributed orchestration of vimentin IFs (FIG. 4])

20

mentary approach to classical genetic studies of disorders of

and actin cytoskeleton (FIG. 4g). Results representative of
n:3 experiments are shown.
Referring back to FIG. 4a, to corroborate that vimentin

25

targeting and not the possible direct inhibition of the 20S

proteasome by WFA mediates its UPP-targeting function,
tests were conducted on WFA in proteasome kinetic assays.

Whereas epoxomicin, a highly selective proteasome inhibi
tor, signi?cantly inhibits the 20S proteasome’s major cata
lytic function at 10 nM, WFA, even at cytotoxic concentra
tions of 10 uM, minimally inhibits this catalytic activity (FIG.
4b). The Kobs/ [I] (M_1S_l), a measure of the ef?ciency of

30

inactivation, was calculated to be 340180 (0.5-10 uM) for

35

IFs, shown in Bar, H., Strelkov, S. V., Sjoberg, G., Aebi, U. &
Herrrnann, H., The biology of desmin ?laments: how do
mutations affect their structure, assembly, and organi sation?,
J. Slrucl. Biol. 148, 137-152 (2004), herein incorporated by
reference. Thus, WFA and derivative steroidal-lactones rep
resent a useful chemical genetic tool for studies of the type-III
IF proteins. As vimentin modulates the immune response and
is overexpressed in prostate and other cancers, WFA holds
great promise as a potential lead for the development of small

molecule therapeutics.
Based on the foregoing experiments and test results, there
are many potential applications for development of small

WFA, while that ofepoxomicin is 44,5 1017,000 (10-75 nM).

molecule based probes and analogs. For example, the binding
of the WFA probe can be used to modulate vimentin protein
function and, thus, the binding pocket can serve as a novel
target for the development of small molecule agonists or

Contrary to a recent report ofYang, H., Shi, G. & Dou, Q. P.,
The tumor proteasome is a primary target for the natural
anticancer compound Withaferin A isolated from “Indian

Winter Cherry,” Mol. Pharmacol. November 8 online (2006),

small molecule can perturb vimentin function. Use of a small
molecule to inhibit vimentin function can serve as a comple

antagonists of vimentin function. In another use, one can
40

herein incorporated by reference, the presently acquired data

monitor intracellular transport and localization of vimentin

protein to different subcellular locations in vivo by conjugat

provides evidence that WFA-modi?ed vimentin may mediate

ing a detection label, such as a ?uorescent tag, radiolabel or

sequestration of ubiquitinated proteins and result in protea

biotin, to WFA. Since these probes bind selectively and

some inhibition in vivo. Thus, employing cell lines derived
from vimentin-de?cient and isogenic wild-type mouse
strains confers enhanced resistance to drug-induced apopto
sis with wild-type cells having a 7-fold greater rate of apop

45

diseases, such as cancer, arthritis, diabetes, etc., serving
essentially as a sensitive diagnostic tool.
In another use, WFA-based analogs can be employed to

tosis (FIG. 40). Furthermore, exploiting a protein transduc

more potently modify vimentin function and thereby generate

tion methodology to introduce the WFA-modi?ed, dominant

negative, vimentin tetramers into cells, immunostaining

50

demonstrates that endogenous vimentin IFs and F-actin are
found to aggregate, whereas cells transduced with vehicle

present in a similar coiled coil domain of the IFs.
55

alterations in the cytoskeleton architecture (FIGS. 4e and 4g).
Since WFA exerts potent angiogenesis inhibitory activity
in vivo, drug activity on de novo capillary growth in vimentin
de?ciency was investigated. The mouse model of injury
induced corneal neovascularization shows that WFA mark

new classes of pharmacological drugs for treatment of human
diseases. In addition, the WFA-vimentin binding site infor

mation could be employed to probe similar binding sites in
other IF proteins, for which the cysteine group is known to be

treated vimentin do not produce this phenotype (compare
FIG. 4d with FIG. 4]). Collectively, these ?ndings demon
strate that vimentin-targeting by WFA can affect the severe

covalently to vimentin, they allow one to follow this marker in
a whole range of known tissues from a variety of proliferative

The following experimental conditions provide additional
background and details regarding the aforementioned experi
ments, which support the present screening method as an

effective method for identifying potential small molecule

drugs and their respective binding sites.
60

All cell culture supplies were purchased from Gibco unless
otherwise speci?ed. Antibodies were from Santasz Bio

edly suppresses neovascularization in wild-type mice (73%
inhibition, n:8; P:0.002), whereas it only marginally attenu

technology unless otherwise speci?ed. WFA and l2-D WS

ates neovascularization in vimentin-null mice (29% inhibi

were obtained from Chromadex and stock solutions were

tion; n:10; P:0.005) (FIG. 5), revealing that inhibition of
capillary growth by WFA is mediated predominantly by

freshly prepared in DMSO. All cell reagents were purchased
65

from Invitrogen.

vimentin. Interestingly, the vascularization response of

HUVECs and BAECs cells were obtained from Cascade

vimentin-de?cient mice is not as extensive as in wild-type

Biologicals and cultured according to vendor’s protocols.
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MCF-7 breast cancer cell line was obtained from ATCC and

and B helices) were built using the (x-helical template struc
ture and the automated homology modeling tool Modeler/

cultured in RPMI 1640 medium containing 10% Fetal Bovine
Serum (FBS). MFT-16 cells from embryo ?broblasts of

InsightII software (Accelrys, Inc.). Then, the best 3D model

vimentin homozygous-de?cient mice (Vim_/_) and MFT-6
cells from embryo ?broblasts of wild-type (Vim+/+) mice

was solvated in water and re?ned by performing a long-time

were obtained from Robert Evans (University of Colorado,

Molecular Docking.
To explore the possible vimentin-ligand binding mode, the

molecular dynamics (MD) simulation in water.

Denver) and cultured in F12:DMEM (1:1) medium supple
mented with 5% FBS. All cells were cultured in humidi?ed

?rst step was to dock the ligand, i.e. WFA or 12-D WS, to

incubators at 370 C.-5% CO2 conditions.

vimentin tetramer fragment by virtue of their geometric
complementarity. The molecular docking for each vimentin

Isolation of WFA-B-Binding Proteins by Af?nity Chroma

tography.

ligand binding was carried out in the same way as previously

The synthesis and chemical characterization of WFA-B,
demonstration of its biological activity in endothelial cells,

done when studying other protein-ligand binding systems, as
disclosed in Hamza, A. & Zhan, C.-G., How Can (—)-Epigal

and use to identify biotinylated proteins from HUVECs was

locatechin Gallate from Green Tea Prevent HIV-1 Infection?

previously reported (Yokota 2006). For scale-up studies,

Mechanistic Insights from Computational Modeling and the
Implication for Rational Design of Anti-HIV-l Entry Inhibi
tors, J. Phys. Chem. B 110, 2910-2917 (2006), herein incor

BAECs were pre-incubated with DMSO or 5 uM WFA for 1

hour and subsequently treated with 5 uM WFA-B for 2 hours.
Cells were washed in ice-cold phosphate buffered saline
(PBS) and cytoplasmic extracts were prepared in BufferA (5
mM Tris, pH 7.6, 50 mM NaF, 1% Triton X-100, 5 mM
EGTA), supplemented with a proteinase inhibitor cocktail
(Roche). After centrifugation, equal amounts of protein were
pre-cleared on agarose beads (Sigma) to remove non-speci?c
agarose-binding proteins. The beads were centrifuged and
pre-cleared cell lysates were repeatedly loaded three times on

porated by reference.
20

A ligand-binding site was de?ned as that consisting of the
residues within a sphere (with a radius of 20 A) centered at

Cys328 residue. The ligand was initially positioned at ~10 A
in front of Cys328 of the binding site. The initial docking
calculations were performed on the ligand with the vimentin
25

fragment binding site using the ‘automatic docking’ Af?nity
module of the InsightII package (Accelrys, Inc.). The Af?nity

columns containing NEUTRAVIDINTM-agarose beads
(Pierce) to maximize immobilization of biotinylated proteins.

methodology uses a combination of Monte Carlo type and

After extensive washing with ice-cold Buffer A, bound bioti
nylated proteins were eluted in Laemeli gel loading buffer

(the ligand) to the host (the receptor). The vimentin-ligand

containing [3-mercaptoethanol and fractioned by SDS-PAGE

simulated Annealing procedures to dock the guest molecule

on 15x15 cm gels. Gels were stained with Coomassie blue

binding structure obtained from the initial docking was fur
ther re?ned by performing an MD simulation in a water bath.

dye and bands corresponding to 56 kDa, 51 kDa and 43 kDa

Western Blotting Experiments.

protein were excised for mass spectrometric analysis.
Identi?cation of Af?nity Puri?ed Proteins by LC-MS/ MS.
All mass spectra reported in this disclosure were acquired

30

After treatments, cells were washed in PBS and extracts
35

by the University of Kentucky Mass Spectrometry Facility.
Gel pieces were digested with trypsin, and LC/MS/MS spec
tra were acquired on a ThermoFinnigan LCQ “Classic” qua

drupole ion trap mass spectrometer (Finnigan Co., San Jose,
Calif.). Separations were performed with an HP 1100 high
performance liquid chromatograph modi?ed with a custom

40

(300 um inner diameter><15 cm). Gradient separations con

x-ray ?lm.
Transfection Studies.

sisted of a 2-minute isocratic step at 95% water and 5%
45

MCF-7 cells were transfected with a pCMV6-XL5 vector

containing the human vimentin cDNA under CMV promoter

organic phase was increased to 20% acetonitrile over 8 min
utes and then increased to 90% acetonitrile over 25 minutes;
held at 90% acetonitrile for 8 minutes and then increased to

95% in 2 minutes; ?nally they were returned to the initial
conditions in 10 minutes (total acquisition time 45 minutes

antibodies were used at 1:1000 dilution. Blots were exten

sively washed in TBST buffer and developed using enhanced
chemiluminescence method (Amersham) and exposed to

splitter to deliver 4 ul/min to a custom C18 capillary column

acetonitrile (both phases contain 0.1% formic acid). The

having equal amounts of proteins were subjected to SDS
PAGE on 4-20% Tris-glycine gels (BioEpress) and trans
ferred to Immun-Blot PVDF membrane (Bio-Rad) using
standard techniques. Primary antibodies were diluted in 5%
non-fat dry milk Tris buffered saline, 0.02% Tween-20
(NFDM-TBST) at the concentration of 1:500, and secondary

according to vendor instructions (Origene). Control samples
were transfected with an empty vector (PCMV6-XL4).
Transfected cells were allowed to recover for 12 hours and
50

subsequently treated with 2 uM WFA for 18 hours. Equal

with a 10 minute recycle time). Tandem mass spectra were

amounts of protein lysates were then subjected to western

acquired in a data-dependent manner. Three micro scans were

blotting and probed with mouse monoclonal antibody against

averaged to generate the data-dependent full-scan spectrum.

ubiquitin proteins.
Protein Transduction Studies.

The most intense ion was subjected to tandem mass spectrom

etry, and three microscans were averaged to produce the

55

(DMSO) for 1 hour at 37° C. to form protein-WFA adducts.
Vimentin-WFA or vimentin alone (0.5 pg) were mixed with

spectra were searched against mammalian proteins in the

Swiss-Prot database using the Mascot search engine (Matrix

Science).

the CHARIOTTM protein transduction reagent (Active Motif)
60

and incubated for 30 minutes at 24° C. to form complex

according to instructions of manufacturer. The protein

3D Model of the Human Vimentin Fragment.
The initial coordinates of 2B human vimentin fragment
used in our computational studies came from the X-ray crys

CHARIOTTM complex was subsequently added to BAECs in
serum-free medium and incubated for 1 hour at 370 C.-5%
CO2 conditions. Fresh complete medium was then added and

tal structure (pdb code: 1gk4.pdb) deposited in the Protein
Data Bank. To encompass the structure of the protein envi

Tetrameric vimentin (0.5 pg) (Cytoskeleton) was incu
bated with 10 uM WFA or an equivalent amount of vehicle

MS/ MS spectrum. Masses subjected to the MS/ MS scan were
placed on an exclusion list for 2 minutes. Resulting MS-MS

65

cells were incubated for an additional 18 hours under normal

ronment surrounding the active residue Cys328, the missing

culture conditions. Cells were processed for immunohis

residues of the 2A fragment (i.e. residues #313 to #327 inA

tochemistry analysis, as described.
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Apoptosis by Flow Cytometry.

gram by nonlinear least squares ?t of the data to the following

To assess the apoptosis activity of WFA, embryonic ?bro
blast vimentin-de?cient cell lines (V1m_/_; MFT-16) and
wild-type (V1m+/+; MFT-6) cells were treated with 5 uM WFA

served t)], where v0 and vs are the initial and ?nal velocities,

or an equivalent amount of vehicle (DMSO) for 24 hours at

range of inhibitor concentrations tested was chosen so that

37° C.-5% CO2 conditions in complete medium. Apoptotic
cells were measured by using the VYBRANTTM Apoptosis

Assay Kit (Molecular Probes) according to the manufactur

several half-lives could be observed during the course of the
measurement. Reactions were performed using inhibitor con
centrations that were <100-fold of those of the proteasome

er’s instructions. Flow cytometric analysis was conducted at

assayed.

the University of Kentucky Core Flow Cytometry Center.
Cell Staining Procedures and Fluorescence Imaging.

Corneal Neovascularization Assays in Mice.

equation: ?uorescenceq/SH [(vO —vS)/k0bse,ved] [1 —exp (—k0bi
respectively, and kobserved is the reaction rate constant. The

Vimentin homozygous-de?cient mice (vim_/_) and vimen
tin-heterozygous-de?cient mice (vim+/_) in the 129/Svev

After treatments, BAECs were washed with PBS and ?xed
with 4% paraformaldehyde for 5 minutes. Cells were then
permeabilized with 0.1% Triton-X in PBS for 20 minutes at
4° C. and blocked for 30 minutes in 3% BSA to prevent

background were obtained from David Markovitz (Univer

sity of Michigan Medical Center) and breeding colonies
established at the University of Kentucky. All mice were

nonspeci?c binding. Rabbit polyclonal vimentin antibody

housed in speci?c pathogen-free cages in designated lab ani

(Vim) or mouse monoclonal vimentin antibody (V9) was
applied to cells for 1 hour at 24° C. at 1:400 dilution in PBS.
After extensive washes with PBS, cells were incubated with

typed by polymerase chain reaction, as described, and vim_/_

anti-rabbit FITC-conjugated secondary antibody (1:500) or
anti-mouse Texas Red-conjugated secondary antibody
(1:500) for 30 minutes. After washing three times with PBS,
cells labeled with Vim-antibody were incubated with phalloi
din conjugated to Rhodamine (1:200) for 20 minutes. After
extensive washes (1-2 hours), cells were visualized using a
Nikon TE2000 microscope.
Transmission Electron Microscopy of Vimentin Filaments.

mal housing facilities. Age-matched littermates were geno
and vim+/+ mice were employed for corneal vascularization
experiments. In brief, mice between 4-6 weeks of age were
20

anesthetized by intraperiteoneal injection (i.p.) of ketamine
and xylazine. Corneas were topically anesthetized by appli
cation of proparacain drop and 1 microliter drop of dilute 0.1
M sodium hydroxide was applied for 1 minute. The cornea
was immediately washed extensively in saline solution and

25

corneal and limbal epithelium gently removed by scraping
with a blunt Tooke corneal knife. The cornea was topically

treated with Atropine eye drop and covered with tobramycin
and erythromycin antibiotic eye ointment. Upon recovery

Tetrameric hamster vimentin was subjected to in vitro ?la

ment formation assays using vendor-supplied reagents and

instructions (Vimentin Filament Biochemistry Kit, Denver,

from anesthesia, mice were replaced in cages and monitored

Colo.). Vimentin (0.5 mg/ml) was mixed with WFA (5 uM or
25 uM), DMSO or 12D-WS (25 uM) in ?lament polymeriza
tion buffer (170 mM NaCl ?nal concentration) and incubated

by trained personnel for resumption of normal activity. WFA

for 1 hour at 37° C. Protein was immediately ?xed in 0.5%

recovery from corneal injury, and subsequently every day

(2 mg/kg solubilized in DMSO) or vehicle (DMSO) was
injected intraperiteoneally in some groups of mice after their

glutarldehyde and stained with uranyl acetate and applied to

after for a period of 10 days. Mice were humanely sacri?ced

copper grids for EM staining (University of Kentucky Core
Microscopy and Imaging Facilities). Over 100 grids for each

and eyes enucleated. Mouse eyes were washed in PBS and
35

mission electron microscope and 25 representative images

dissected in half to obtain anterior segment half. The scleral
tissue was carefully removed and corneal buttons were pre
pared. Corneal tissues were ?xed in 100% acetone for 20

were collected. The experiment was repeated in entirety.

minutes, washed in PBS for 1 hour and blocked for 18 hours

treatment were viewed at 80 kV on a FEI Biotwin 12 trans

Enzyme Kinetic Studies.

in 1% BSA-PBS at 4° C. Cornea whole mount staining was

kaSSOCZ-a?on values were determined as follows. Inhibitors
were mixed with a ?uorogenic peptide substrate and assay
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mouse CD31 antibody (BD Pharmingen; 1:333 dilution in

buffer (20 mM Tris (pH 8.0), 0.5 mM EDTA, and 0.035%
SDS) in a 96-well plate. The chymotrypsin-like activity was

assayed using the ?uorogenic peptide substrates Suc-Leu
Leu-Val-Tyr-AMC (Sigma-Aldrich). Hydrolysis was initi
ated by the addition of bovine 20S proteasome, and the reac
tion was followed by ?uorescence (360-nm excitation/460
nm detection) using a Microplate Fluorescence Reader

45

Winooski, Vt.). Reactions were allowed to proceed for 60-90
minutes, and ?uorescence data were collected every 1 minute.
Fluorescence was quanti?ed as arbitrary units and progres
sion curves were plotted for each reaction as a function of

time. kobserved/[I] values were obtained using PRISM pro

SEQUENCE LISTING

<l60> NUMBER OF SEQ ID NOS:

<210> SEQ ID NO 1
<211> LENGTH:
<212> TYPE:
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PRT

<213> ORGANISM: Homo sapiens

l4

1% BSA-PBS) for 12 hours. Excess stain was washed away
by incubation for 24 hours at 4° C. in 1% BSA-PBS. Corneal
whole mounts were a?ixed to glass slides, cover-slipped and
photographed on a Nikon TE2000 microscope. Fluorescence

was quanti?ed by importing images in NIH Image], as taught
by Ambati, B. K. et al., Sustained inhibition of corneal

(FL600; Bio-Tek Instruments, Inc., Winnoski, Vt.) employ
ing the software KC4 v.2.5 (Bio-Tek Instruments, Inc.,

performed by incubating tissues in FITC-conjugated rat anti
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neovascularization by genetic ablation of CCR5, Invest.
Oplhalmol. st. Sci. 44, 590-593 (2003), hereinafter incorpo
rated by reference.
Although the invention has been described in considerable
detail with respect to preferred embodiments, it will be appar
ent that the invention is capable of numerous modi?cations

and variations, apparent to those skilled in the art, without
departing from the spirit and scope of the claims.

